61 related articles for article (PubMed ID: 5038771)
1. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.
Sliwinski AJ; Zvaifler NJ
Clin Exp Immunol; 1972 May; 11(1):21-9. PubMed ID: 5038771
[TBL] [Abstract][Full Text] [Related]
2. Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.
Bansal L; Nichols EM; Howsmon DP; Neisen J; Bessant CM; Cunningham F; Petit-Frere S; Ludbrook S; Damian V
Front Pharmacol; 2022; 13():855743. PubMed ID: 35517827
[No Abstract] [Full Text] [Related]
3. Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus.
Raymond W; Eilertsen G; Nossent J
J Immunol Res; 2018; 2018():8051972. PubMed ID: 30687766
[TBL] [Abstract][Full Text] [Related]
4. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
5. Complement and systemic lupus erythematosus.
Walport MJ
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S279-93. PubMed ID: 12110148
[TBL] [Abstract][Full Text] [Related]
6. Pleuropulmonary manifestations of systemic lupus erythematosus.
Keane MP; Lynch JP
Thorax; 2000 Feb; 55(2):159-66. PubMed ID: 10639536
[No Abstract] [Full Text] [Related]
7. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.
Swaak AJ; Hannema A; Vogelaar C; Boom FA; van Es L; van Aalst R; Statius van Eps LW
Rheumatol Int; 1982; 2(4):161-6. PubMed ID: 6984977
[TBL] [Abstract][Full Text] [Related]
8. Complement-mediated delay in immune complex clearance from the blood owing to reduced deposition outside the reticuloendothelial system.
Skogh T; Stendahl O
Immunology; 1983 May; 49(1):53-9. PubMed ID: 6404812
[TBL] [Abstract][Full Text] [Related]
9. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
Charlesworth JA; Williams DG; Sherington E; Lachmann PJ; Peters DK
J Clin Invest; 1974 Jun; 53(6):1578-87. PubMed ID: 4830223
[TBL] [Abstract][Full Text] [Related]
10. Complement metabolism in rheumatoid arthritis. I. Longitudinal studies.
Versey JM; Hobbs JR; Holt PJ
Ann Rheum Dis; 1973 Nov; 32(6):557-64. PubMed ID: 4148547
[No Abstract] [Full Text] [Related]
11. Complement activation and complement receptors in systemic lupus erythematosus.
Atkinson JP
Springer Semin Immunopathol; 1986; 9(2-3):179-94. PubMed ID: 3544279
[No Abstract] [Full Text] [Related]
12. C3 degradation products (C3d) in normal pregnancy.
Jenkins JS; Powell RJ
J Clin Pathol; 1987 Nov; 40(11):1362-3. PubMed ID: 3500968
[TBL] [Abstract][Full Text] [Related]
13. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.
Doherty M; Richards N; Hornby J; Powell R
Ann Rheum Dis; 1988 Mar; 47(3):190-7. PubMed ID: 2833185
[TBL] [Abstract][Full Text] [Related]
14. In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.
Hugo F; Berstecher C; Krämer S; Fassbender W; Bhakdi S
Clin Exp Immunol; 1989 Jul; 77(1):112-6. PubMed ID: 2766574
[TBL] [Abstract][Full Text] [Related]
15. Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?
Peakman M; Senaldi G; Vergani D
J Clin Pathol; 1989 Oct; 42(10):1018-25. PubMed ID: 2685048
[No Abstract] [Full Text] [Related]
16. Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus.
Tsukamoto H; Ueda A; Nagasawa K; Tada Y; Niho Y
Clin Exp Immunol; 1990 Nov; 82(2):257-61. PubMed ID: 2242606
[TBL] [Abstract][Full Text] [Related]
17. Significance of low molecular weight C1q in systemic lupus erythematosus.
Hoekzema R; Swaak AJ; Brouwer MC; van Rooijen A; Nieuwenhuys EJ; Hack CE
Ann Rheum Dis; 1990 Sep; 49(9):698-704. PubMed ID: 2241286
[TBL] [Abstract][Full Text] [Related]
18. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
19. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.
Sissons JG; Liebowitch J; Amos N; Peters DK
J Clin Invest; 1977 Apr; 59(4):704-15. PubMed ID: 845257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
